Tyr397

Site Information
sVsEtDDyAEIIDEE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 447887
Available spectra: 5 CST
Associated spectra: 7 CST

In vivo Characterization
Methods used to characterize site in vivo:	flow cytometry ( 22 ) , immunoassay ( 11 , 12 , 22 , 23 , 26 , 29 , 30 , 32 , 37 , 41 , 45 , 46 , 48 , 49 , 55 , 58 , 90 , 121 , 176 ) , immunoprecipitation ( 39 , 69 , 70 , 71 , 73 , 74 , 76 , 80 , 81 , 88 , 89 , 97 , 103 , 115 , 172 , 189 , 225 , 603 , 609 , 610 ) , mass spectrometry ( 84 , 98 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 116 , 119 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 136 , 137 , 138 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 160 , 161 , 162 , 163 , 164 , 165 , 168 , 169 , 170 , 173 , 174 , 178 , 179 , 180 , 181 , 182 , 183 , 185 , 186 , 187 , 190 , 191 , 194 , 196 , 197 , 200 , 201 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 222 , 223 , 224 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 248 , 249 , 250 , 251 , 252 , 253 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 268 , 269 , 270 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 279 , 281 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 289 , 290 , 291 , 292 , 293 , 294 , 295 , 297 , 298 , 299 , 301 , 302 , 307 , 308 , 309 , 310 , 316 , 317 , 318 , 319 , 320 , 321 , 322 , 323 , 324 , 325 , 326 , 327 , 328 , 329 , 330 , 331 , 333 , 337 , 338 , 339 , 340 , 341 , 342 , 343 , 344 , 345 , 346 , 348 , 349 , 350 , 351 , 352 , 353 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 , 368 , 369 , 370 , 371 , 372 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 402 , 403 , 404 , 405 , 406 , 407 , 408 , 409 , 410 , 411 , 413 , 414 , 416 , 421 , 422 , 423 , 425 , 426 , 427 , 428 , 429 , 430 , 431 , 432 , 433 , 435 , 438 , 439 , 441 , 442 , 443 , 444 , 445 , 447 , 448 , 449 , 450 , 451 , 452 , 453 , 454 , 455 , 456 , 457 , 458 , 459 , 460 , 461 , 462 , 463 , 464 , 465 , 466 , 468 , 469 , 470 , 471 , 473 , 474 , 475 , 477 , 478 , 479 , 480 , 481 , 482 , 483 , 484 , 485 , 487 , 488 , 489 , 490 , 491 , 492 , 493 , 494 , 495 , 496 , 497 , 498 , 499 , 500 , 501 , 502 , 503 , 505 , 506 , 507 , 511 , 512 , 513 , 516 , 518 , 519 , 521 , 522 , 523 , 525 , 526 , 527 , 528 , 531 , 532 , 533 , 534 , 535 , 537 , 538 , 539 , 540 , 541 , 542 , 543 , 544 , 545 , 546 , 547 , 548 , 549 , 550 , 551 , 552 , 554 , 555 , 556 , 557 , 558 , 559 , 560 , 563 , 564 , 567 , 614 ) , microscopy-colocalization with upstream kinase ( 189 ) , mutation of modification site ( 30 , 31 , 39 , 68 , 69 , 70 , 75 , 76 , 79 , 81 , 85 , 89 , 97 , 99 , 172 , 176 , 303 , 304 , 305 , 418 , 420 , 424 , 472 , 510 , 514 , 524 , 536 , 561 , 575 , 577 , 589 , 603 , 607 , 609 , 610 , 611 ) , phospho-antibody ( 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 54 , 55 , 56 , 57 , 58 , 59 , 61 , 62 , 63 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 85 , 87 , 89 , 90 , 91 , 92 , 94 , 95 , 96 , 97 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 114 , 115 , 117 , 118 , 120 , 121 , 122 , 123 , 140 , 141 , 142 , 143 , 144 , 159 , 166 , 167 , 171 , 172 , 175 , 176 , 177 , 184 , 188 , 189 , 192 , 193 , 195 , 198 , 199 , 202 , 203 , 221 , 225 , 254 , 255 , 271 , 280 , 296 , 303 , 304 , 305 , 311 , 312 , 313 , 314 , 315 , 332 , 334 , 335 , 336 , 347 , 373 , 412 , 415 , 417 , 418 , 419 , 420 , 424 , 434 , 436 , 437 , 440 , 446 , 467 , 472 , 476 , 486 , 504 , 508 , 509 , 510 , 514 , 515 , 517 , 520 , 524 , 529 , 530 , 536 , 553 , 561 , 562 , 565 , 566 , 568 , 569 , 570 , 571 , 572 , 573 , 574 , 575 , 576 , 577 , 578 , 579 , 580 , 581 , 582 , 583 , 584 , 585 , 586 , 587 , 588 , 589 , 590 , 591 , 592 , 593 , 594 , 595 , 596 , 597 , 598 , 599 , 600 , 601 , 602 , 603 , 604 , 605 , 606 , 607 , 608 , 611 , 612 , 613 ) , phosphoamino acid analysis ( 306 ) , western blotting ( 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 24 , 25 , 27 , 28 , 30 , 31 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 47 , 48 , 49 , 50 , 51 , 52 , 54 , 56 , 57 , 58 , 59 , 61 , 62 , 63 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 85 , 87 , 89 , 90 , 91 , 92 , 94 , 95 , 96 , 97 , 100 , 101 , 102 , 103 , 104 , 105 , 114 , 115 , 117 , 118 , 120 , 121 , 122 , 123 , 140 , 141 , 142 , 143 , 144 , 159 , 166 , 167 , 171 , 172 , 175 , 177 , 184 , 188 , 189 , 193 , 195 , 198 , 199 , 202 , 203 , 221 , 225 , 254 , 255 , 271 , 280 , 296 , 304 , 305 , 306 , 311 , 312 , 313 , 314 , 315 , 334 , 336 , 347 , 373 , 415 , 417 , 418 , 419 , 420 , 424 , 434 , 436 , 437 , 440 , 446 , 467 , 472 , 504 , 510 , 514 , 520 , 524 , 529 , 553 , 561 , 565 , 568 , 569 , 570 , 572 , 573 , 579 , 580 , 583 , 586 , 591 , 599 , 601 , 603 , 604 , 606 , 607 , 608 , 609 , 610 , 611 , 612 , 613 )
Disease tissue studied:	adenoid cystic carcinoma ( 257 , 258 ) , bile-duct cancer ( 247 ) , bladder cancer ( 27 , 344 , 345 , 376 ) , bone cancer ( 29 , 61 , 102 , 117 , 301 , 302 , 310 , 472 , 513 ) , osteosarcoma ( 301 , 302 , 310 , 472 , 513 ) , brain cancer ( 119 , 141 , 152 , 159 , 169 , 188 , 205 , 280 , 393 , 443 , 444 , 445 , 455 , 456 , 496 , 561 ) , astrocytoma ( 152 , 393 , 496 ) , glioblastoma ( 141 , 159 , 169 , 188 , 205 , 443 , 444 , 445 , 455 , 456 , 561 ) , glioblastoma multiforme ( 119 , 159 , 444 , 455 , 456 ) , glioma ( 119 , 141 , 159 , 169 , 188 , 205 , 443 , 444 , 445 , 455 , 456 , 561 ) , breast cancer ( 5 , 6 , 8 , 12 , 15 , 26 , 38 , 44 , 49 , 50 , 56 , 70 , 73 , 75 , 77 , 89 , 104 , 106 , 144 , 189 , 192 , 195 , 199 , 225 , 235 , 254 , 303 , 306 , 340 , 341 , 342 , 351 , 352 , 353 , 354 , 355 , 356 , 357 , 358 , 363 , 374 , 377 , 400 , 401 , 415 , 447 , 448 , 449 , 457 , 484 , 485 , 506 , 507 , 522 , 523 , 567 , 570 ) , breast adenocarcinoma ( 104 , 448 , 567 ) , breast ductal carcinoma ( 449 ) , HER2 positive breast cancer ( 84 ) , luminal A breast cancer ( 84 ) , luminal B breast cancer ( 84 ) , breast cancer, triple negative ( 12 , 84 , 104 , 355 , 356 , 447 , 449 , 457 ) , colorectal cancer ( 18 , 52 , 92 , 94 , 136 , 137 , 138 , 150 , 151 , 158 , 312 , 315 , 336 , 347 , 382 , 384 , 408 , 409 , 410 , 413 , 414 , 422 , 423 , 432 , 433 , 437 , 452 , 471 , 475 , 494 , 495 , 498 , 499 , 504 , 514 , 533 , 534 , 540 , 541 , 558 , 559 , 576 , 586 ) , colorectal carcinoma ( 18 , 52 , 92 , 94 , 136 , 137 , 138 , 150 , 151 , 158 , 312 , 315 , 336 , 347 , 382 , 384 , 408 , 409 , 410 , 413 , 414 , 422 , 423 , 432 , 433 , 452 , 471 , 475 , 494 , 495 , 498 , 499 , 504 , 514 , 533 , 534 , 540 , 541 , 558 , 559 , 586 ) , endometrial cancer ( 51 ) , endometrial adenocarcinoma ( 51 ) , esophageal cancer ( 7 , 19 , 23 , 55 , 240 , 366 , 367 , 368 , 385 , 386 , 387 , 395 , 396 , 397 , 398 , 425 , 426 , 427 , 430 ) , esophageal carcinoma ( 7 , 19 , 23 , 55 , 366 , 367 , 368 , 395 , 396 , 398 ) , esophageal cancer, surrounding tissue ( 239 ) , gallbladder cancer ( 253 ) , gastric cancer ( 21 , 30 , 32 , 96 , 132 , 133 , 134 , 197 , 200 , 206 , 208 , 209 , 211 , 212 , 213 , 261 , 281 , 282 , 283 , 284 , 285 , 289 , 290 , 291 , 292 , 293 , 321 , 364 , 411 ) , gastric carcinoma ( 21 , 30 , 32 , 54 , 96 , 132 , 133 , 134 , 200 , 261 , 284 , 321 , 411 ) , gastric carcinoma, surrounding tissue ( 207 , 210 , 260 ) , HNSCC ( 123 ) , kidney cancer ( 14 , 343 ) , leukemia ( 438 , 553 , 609 ) , acute myelogenous leukemia ( 438 , 553 ) , liver cancer ( 40 , 48 , 58 , 80 , 91 , 103 , 198 , 220 , 224 , 227 , 228 , 242 , 248 , 252 , 263 , 272 , 274 , 275 , 418 ) , liver adenocarcinoma ( 198 ) , cholangiocellular carcinoma ( 48 , 418 ) , hepatocellular carcinoma ( 40 , 58 , 80 , 91 , 103 , 198 , 220 , 224 , 227 , 228 , 242 , 272 , 275 ) , hepatocellular carcinoma, surrounding tissue ( 222 , 223 , 241 , 273 ) , lung cancer ( 34 , 57 , 67 , 71 , 97 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 115 , 121 , 126 , 127 , 128 , 129 , 130 , 131 , 140 , 142 , 143 , 145 , 146 , 147 , 148 , 149 , 153 , 154 , 155 , 156 , 157 , 160 , 161 , 162 , 163 , 164 , 165 , 175 , 177 , 191 , 194 , 200 , 204 , 215 , 216 , 217 , 229 , 230 , 231 , 232 , 233 , 234 , 243 , 244 , 245 , 251 , 262 , 277 , 278 , 288 , 295 , 296 , 314 , 316 , 317 , 318 , 319 , 320 , 322 , 323 , 324 , 325 , 326 , 327 , 328 , 329 , 330 , 331 , 333 , 334 , 337 , 338 , 339 , 346 , 357 , 358 , 365 , 378 , 379 , 380 , 381 , 388 , 389 , 390 , 391 , 392 , 402 , 403 , 404 , 405 , 406 , 407 , 431 , 435 , 439 , 441 , 442 , 450 , 453 , 458 , 459 , 460 , 461 , 462 , 463 , 464 , 465 , 466 , 468 , 469 , 470 , 474 , 477 , 478 , 479 , 480 , 481 , 482 , 487 , 488 , 490 , 492 , 493 , 497 , 501 , 503 , 505 , 511 , 512 , 516 , 519 , 520 , 521 , 525 , 526 , 527 , 528 , 546 , 547 , 548 , 550 , 551 , 552 , 554 , 555 , 556 , 557 , 563 , 580 , 601 , 613 ) , non-small cell lung cancer ( 34 , 57 , 67 , 71 , 97 , 107 , 108 , 109 , 111 , 112 , 113 , 115 , 116 , 121 , 126 , 127 , 128 , 129 , 130 , 131 , 145 , 146 , 147 , 148 , 149 , 153 , 154 , 155 , 156 , 157 , 160 , 161 , 162 , 163 , 164 , 165 , 191 , 204 , 215 , 216 , 217 , 229 , 230 , 231 , 243 , 251 , 262 , 277 , 278 , 288 , 295 , 296 , 316 , 320 , 322 , 323 , 324 , 325 , 327 , 328 , 329 , 330 , 331 , 333 , 337 , 339 , 365 , 378 , 379 , 380 , 381 , 388 , 389 , 390 , 391 , 392 , 402 , 403 , 404 , 405 , 406 , 407 , 431 , 435 , 439 , 442 , 450 , 453 , 458 , 459 , 460 , 461 , 462 , 463 , 464 , 465 , 466 , 468 , 469 , 470 , 477 , 478 , 479 , 480 , 481 , 482 , 487 , 490 , 492 , 493 , 501 , 503 , 505 , 511 , 516 , 519 , 520 , 521 , 525 , 526 , 527 , 528 , 546 , 547 , 548 , 550 , 551 , 552 , 554 , 555 , 556 , 557 , 563 ) , non-small cell lung adenocarcinoma ( 34 , 57 , 67 , 71 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 116 , 121 , 147 , 148 , 149 , 155 , 156 , 157 , 160 , 161 , 162 , 163 , 164 , 165 , 200 , 204 , 215 , 216 , 229 , 230 , 243 , 262 , 277 , 278 , 288 , 295 , 320 , 322 , 323 , 329 , 330 , 331 , 346 , 357 , 358 , 466 , 480 ) , non-small cell large cell lung carcinoma ( 34 , 57 , 97 , 108 , 111 ) , non-small cell squamous cell lung carcinoma ( 110 , 200 , 232 , 233 , 234 , 244 , 245 , 288 , 322 , 323 , 439 , 458 , 461 , 469 , 470 , 503 , 555 ) , small-cell lung cancer ( 177 , 441 , 488 , 580 ) , lymphoma ( 573 ) , nasopharyngeal carcinoma ( 100 ) , neuroblastoma ( 98 , 193 , 280 , 349 , 350 , 359 , 360 , 361 , 612 ) , ovarian cancer ( 10 , 41 , 106 , 170 , 178 , 179 , 180 , 181 , 182 , 184 , 186 , 187 , 308 , 416 , 421 , 451 ) , ovarian epithelial carcinoma ( 106 , 170 ) , pancreatic cancer ( 25 , 26 , 79 , 93 , 218 , 219 , 271 , 531 , 532 , 537 , 538 , 539 , 542 , 543 , 549 ) , pancreatic carcinoma ( 25 , 26 , 79 , 93 , 218 , 219 , 271 , 531 , 532 , 537 , 538 , 539 , 542 , 543 , 549 ) , multiple myeloma ( 87 ) , prostate cancer ( 24 , 28 , 65 , 90 , 311 , 434 , 535 , 560 , 604 ) , melanoma skin cancer ( 17 , 68 , 195 , 246 ) , non-melanoma skin cancer ( 544 , 545 ) , cancer, squamous cell carcinoma ( 9 , 123 , 568 , 571 ) , ventricular tachycardia ( 168 )
Relevant cell line - cell type - tissue:	'liver, para-cholangiocellular carcinoma tissue' ( 173 ) , 'pancreatic, ductal'-pancreas ( 22 ) , 'stem, mesenchymal' ( 45 , 59 ) , 143.98.2 (bone cell) ( 310 ) , 143B (bone cell) ( 302 ) , 184A1 (epithelial) [HER2 (human), transfection] ( 369 ) , 184A1 (epithelial) ( 369 ) , 22Rv1 (prostate cell) ( 24 , 65 ) , 23132/87 (gastric) ( 411 ) , 293 (epithelial) [EFNB1 (human), transfection] ( 201 ) , 293 (epithelial) [EphB2 (human), transfection] ( 201 ) , 293 (epithelial) ( 73 , 74 , 88 , 172 , 176 , 189 , 332 , 420 , 486 , 565 , 593 , 603 ) , 3AO (ovarian) ( 41 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 332 , 517 , 536 , 575 , 590 , 598 ) , 3T3 (fibroblast) ( 118 , 306 , 510 , 610 ) , 4T1 (breast cell) ( 12 ) , 5637 (bladder cell) ( 27 , 376 ) , 639V (renal) ( 343 ) , 769P (renal) ( 14 ) , 786-O (renal) ( 14 ) , A2780 (ovarian) ( 41 ) , A375 (melanocyte) ( 68 ) , A431 (epithelial) [FAK (human)] ( 313 ) , A431 (epithelial) ( 544 , 545 ) , A498 (renal) ( 14 , 190 ) , A549 (pulmonary) [LKB1 (human), no information] ( 278 ) , A549 (pulmonary) ( 57 , 67 , 107 , 121 , 140 , 142 , 175 , 229 , 277 , 296 , 314 , 317 , 318 , 319 , 326 , 334 , 497 , 520 , 563 , 601 ) , ACC-S (adenoidal) ( 256 ) , ACHN (renal) ( 14 ) , ACN ( 98 , 360 ) , adipose tissue ( 59 ) , AGS (gastric) ( 30 , 32 ) , AU565 (breast cell) ( 351 , 352 ) , AZ-521 (gastric) ( 282 ) , BAEC (endothelial) ( 524 , 596 ) , BEL7402 (hepatic) ( 91 ) , BGC823 (gastric) ( 54 , 96 ) , BL62 ( 21 ) , BPAEC ( 419 , 588 ) , breast ( 8 , 84 , 363 , 377 ) , BT-474 (breast cell) ( 235 , 577 ) , BT-549 (breast cell) ( 12 ) , BxPC-3 (pancreatic) ( 79 , 332 ) , C4-2B (prostate cell) ( 90 ) , C8161 (melanocyte) ( 17 , 195 ) , Caco-2 (intestinal) ( 52 , 336 , 476 ) , Caki-1 (renal) ( 14 ) , Caki-2 (renal) ( 375 ) , Cal-12T (pulmonary) ( 113 ) , CAL-29 (bladder cell) ( 345 ) , CAL-51 (breast cell) ( 353 , 354 ) , Calu-3 (pulmonary) ( 109 , 512 , 520 ) , Caov-3 (ovarian) ( 41 , 106 ) , Capan1 (pancreatic) ( 79 , 93 ) , CD18/HPAF (pancreatic) ( 93 ) , CHO (fibroblast) [EphB1 (human), transfection] ( 603 ) , CHO (fibroblast) ( 82 , 510 ) , COLO-680N (esophageal) ( 397 ) , colon ( 576 ) , COS (fibroblast) ( 440 , 472 , 515 , 585 , 598 , 611 ) , COS7 (fibroblast) ( 75 , 176 ) , COV504 (ovarian) ( 41 ) , DBTRG-05MG (glial) ( 455 ) , DE66 ( 21 ) , DMS153 (pulmonary) ( 112 ) , DMS53 (pulmonary) ( 488 ) , DU 145 (prostate cell) ( 560 , 604 ) , DU4475 (breast cell) ( 566 ) , EFM-19 (breast cell) ( 383 ) , EFO-21 (ovarian) ( 421 ) , endothelial ( 83 ) , endothelial-pulmonary artery ( 508 ) , epithelial-prostate ( 434 ) , esophagus ( 239 , 240 ) , EVSA-T (breast cell) ( 400 ) , FaDu (squamous) ( 123 ) , FG (pancreatic) ( 313 ) , fibroblast ( 45 ) , fibroblast-foreskin ( 575 ) , fibroblast-skin ( 26 ) , FLO-1 ( 19 ) , FU-OV-1 (ovarian) ( 416 ) , FU97 (gastric) ( 197 ) , GES-1 ( 30 ) , GI-CA-N (neural crest) ( 349 ) , GI-LI-N (neuron) ( 98 , 361 ) , GI-ME-N (neuron) ( 98 , 359 ) , glial-brain ( 119 ) , H157 ( 36 ) , H413 ( 36 ) , HBE (epithelial) ( 520 ) , HBEC76-KT ( 66 ) , HBL-100 (breast cell) ( 144 ) , HBMEC (endothelial) ( 607 ) , HCC1143 (breast cell) ( 449 ) , HCC1428 (breast cell) ( 448 ) , HCC15 (pulmonary) ( 110 ) , HCC1599 (breast cell) ( 340 ) , HCC1806 (breast cell) ( 457 ) , HCC1937 (breast cell) ( 447 ) , HCC366 (pulmonary) ( 492 ) , HCC44 (pulmonary) ( 113 , 482 ) , HCC70 (breast cell) ( 355 , 356 ) , HCC78 (pulmonary) ( 111 , 149 , 156 , 157 , 481 ) , HCC827 (pulmonary) ( 71 , 109 , 295 , 320 , 329 , 330 , 331 , 466 ) , HCT116 (intestinal) ( 18 , 92 , 94 , 136 , 137 , 138 , 150 , 151 , 158 , 382 , 410 , 498 , 499 , 533 , 534 ) , HCT15 (intestinal) ( 422 ) , HCT8 (intestinal) ( 423 ) , heart ( 168 , 279 , 606 ) , HEK293T (epithelial) ( 4 , 34 , 35 , 62 , 67 , 70 , 81 , 99 , 510 , 518 , 605 ) , HeLa (cervical) ( 8 , 68 , 74 , 99 , 105 , 114 , 122 , 264 , 268 , 269 , 270 ) , Hep 3B2.1-7 (hepatic) ( 80 , 198 ) , Hep3B (hepatic) ( 40 ) , hepatic-'liver, para-hepatocellular carcinoma tissue' ( 222 , 223 , 241 , 273 ) , hepatocyte-liver ( 220 , 224 , 272 , 275 ) , HepG2 (hepatic) ( 40 , 58 , 91 , 198 , 228 , 592 ) , HES-3 ('stem, embryonic') ( 174 ) , HFF1 (fibroblast) ( 167 ) , HGC-27 (gastric) ( 30 ) , HL60 (myeloid) [FAK (human), transfection] ( 609 ) , HLF (hepatic) ( 227 ) , HMEC (endothelial) ( 120 , 446 ) , HMVEC (endothelial) ( 417 ) , HN30 ( 9 ) , HN31 ( 9 ) , HOS (bone cell) ( 301 , 574 ) , HOSEpics (ovarian) ( 41 ) , HPAC (pancreatic) ( 219 ) , HPAEC (endothelial) ( 569 , 582 ) , Hs766T (pancreatic) ( 532 , 549 ) , HT-29 (intestinal) ( 18 , 347 , 413 , 414 , 475 , 494 , 495 , 500 , 540 , 541 , 558 , 559 , 597 ) , HT1080 (fibroblast) ( 574 ) , HuCCT1 (hepatic) ( 48 ) , Huh1 (hepatic) ( 242 ) , Huh6 (hepatic) ( 263 ) , Huh7 (hepatic) ( 40 , 80 , 198 ) , HUVEC (endothelial) ( 13 , 39 , 42 , 47 , 85 , 100 , 202 , 255 , 259 , 412 , 436 , 529 , 578 , 594 , 599 , 603 , 608 ) , IEC-18 (epithelial) ( 315 , 332 ) , IGROV1 (ovarian) ( 581 ) , IM95 (gastric) ( 30 , 283 ) , IMR-90 (fibroblast) ( 574 , 579 ) , IOSE-29 (ovarian) ( 581 ) , Ishikawa (Heraklio) 02 ER- (endometrial) ( 51 ) , J82 (bladder cell) ( 27 ) , JHH-5 (hepatic) ( 252 ) , JHH-6 (hepatic) ( 248 ) , JIMT-1 (breast cell) ( 374 , 401 ) , Jurkat (T lymphocyte) ( 286 , 287 , 294 , 297 , 298 , 299 ) , Kasumi-1 (myeloid) ( 438 ) , keratinocyte ( 43 , 72 ) , KG-1 (myeloid) ( 562 ) , kidney ( 33 ) , KKU-213A ( 48 ) , KPC ( 63 ) , Kyse140 (esophageal) ( 366 , 367 , 368 ) , Kyse150 (esophageal) ( 55 ) , Kyse270 (esophageal) ( 385 , 386 , 387 , 425 ) , Kyse30 (esophageal) ( 55 ) , Kyse410 (esophageal) ( 23 , 55 , 430 ) , Kyse450 (squamous) ( 7 , 427 ) , Kyse510 (esophageal) ( 7 , 23 , 426 ) , Kyse520 (esophageal) ( 19 ) , Kyse70 (esophageal) ( 19 , 395 , 396 , 398 ) , L3.6p1 (pancreatic) ( 313 ) , LAN-1 (neural crest) ( 350 ) , larynx ( 571 ) , LCLC-103H (pulmonary) ( 402 ) , liver ( 34 , 37 , 48 , 198 , 274 ) , LLC-PK1 (renal) ( 467 , 600 ) , LN18 (glial) ( 444 ) , LN229 (glial) ( 159 , 188 , 445 ) , LN405 (glial) ( 393 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFR (wildtype)] ( 169 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFRvIII mutant (aka Delta EGFR, d2-7 EGFR; del. exon 2-7; in-frame loss 801 bp/267 aa in EC domain)] ( 169 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFRvIII-ki mutant (deletion of exons 2-7 plus kinase inactive mutation)] ( 169 ) , LN444 (glial) ( 205 ) , LNCaP (prostate cell) ( 65 , 604 ) , LOU-NH91 (squamous) ( 110 , 439 , 461 ) , Ls174T (intestinal) ( 587 ) , lung ( 107 , 108 , 109 , 110 , 111 , 112 , 113 , 160 , 161 , 162 , 163 , 164 , 165 , 194 , 204 , 232 , 233 , 234 , 243 , 244 , 245 , 262 , 333 , 337 , 338 , 339 , 378 , 380 , 381 , 388 , 389 , 390 , 391 , 392 , 407 , 428 , 429 , 435 , 453 , 454 , 459 , 473 , 483 , 489 , 490 , 491 ) , LXF-289 (pulmonary) ( 403 ) , M059J (glial) ( 443 ) , macrophage-blood ( 515 ) , mammary gland ( 303 ) , MCF-10A (breast cell) [CSFR (human), transfection] ( 183 ) , MCF-10A (breast cell) ( 183 , 484 , 485 , 506 , 507 , 522 , 523 , 577 ) , MCF-7 (breast cell) [Src (human)] ( 415 ) , MCF-7 (breast cell) ( 26 , 89 , 106 , 189 , 199 , 225 , 303 , 509 , 567 , 577 ) , MCF10A1 (epithelial) ( 46 ) , MDA-MB-231 (breast cell) [Syk (human), transfection, Tet-reponsive Syk-inducible system] ( 185 ) , MDA-MB-231 (breast cell) ( 5 , 6 , 12 , 15 , 38 , 44 , 49 , 50 , 56 , 70 , 73 , 75 , 77 , 144 , 185 , 195 , 306 , 566 ) , MDA-MB-361 (breast cell) ( 306 ) , MDA-MB-435S (breast cell) ( 226 ) , MDA-MB-468 (breast cell) ( 104 ) , MDA-PCa 118b (prostate cell) ( 90 ) , MDA-PCa-2b ( 65 ) , MDCK (epithelial) ( 172 , 313 , 520 ) , MDCKII (epithelial) ( 69 ) , MEEC (epithelial) ( 120 ) , MEF (fibroblast) [FAK (human), transfection] ( 166 ) , MEF (fibroblast) [PTP1B (mouse)] ( 440 ) , MEF (fibroblast) ( 20 , 71 , 118 , 280 , 418 ) , mesangial-kidney ( 304 ) , MHCC97H (hepatic) ( 91 ) , MIA PaCa (pancreatic) ( 271 ) , MIA PaCa-2 (pancreatic) ( 26 , 79 , 537 , 538 , 539 ) , MKN-1 (gastric) ( 284 ) , MKN-28 (gastric) ( 30 ) , MKN-45 (gastric) ( 30 , 132 , 133 , 134 , 200 , 321 ) , MKN-7 (gastric) ( 291 ) , MKN-74 (gastric) ( 292 ) , MNNG-HOS (bone cell) ( 513 ) , MT-3 (breast cell) ( 357 , 358 ) , MuM-2B ( 17 ) , MuM-2C ( 17 ) , MV4-11 (macrophage) ( 226 ) , myeloid ( 562 ) , myocyte-heart ( 76 , 572 , 606 ) , NBT-II (bladder cell) ( 530 ) , NCI-H1299 (pulmonary) ( 67 , 71 , 97 , 108 , 115 , 191 ) , NCI-H1355 (pulmonary) ( 107 ) , NCI-H1373 (pulmonary) ( 546 , 547 ) , NCI-H1435 (pulmonary) ( 450 ) , NCI-H1437 (pulmonary) ( 112 , 113 , 478 , 520 ) , NCI-H1568 (pulmonary) ( 477 ) , NCI-H1650 (pulmonary) ( 71 , 109 , 126 , 127 , 128 , 129 , 130 , 131 , 145 , 146 , 153 , 154 , 230 , 295 , 464 , 519 , 525 , 564 ) , NCI-H1666 (pulmonary) ( 113 , 295 , 465 , 511 , 516 , 527 ) , NCI-H1703 (squamous) ( 110 , 200 , 236 , 237 , 238 , 249 , 250 , 251 , 288 , 316 , 322 , 323 , 493 , 548 ) , NCI-H1734 (pulmonary) ( 108 , 295 , 460 , 528 ) , NCI-H1781 (pulmonary) ( 111 , 365 ) , NCI-H1792 (pulmonary) ( 107 , 520 ) , NCI-H1793 (pulmonary) ( 463 ) , NCI-H1869 (squamous) ( 458 ) , NCI-H1944 (pulmonary) ( 108 , 480 ) , NCI-H1975 (pulmonary) ( 34 , 109 , 521 , 526 ) , NCI-H2023 (pulmonary) ( 462 ) , NCI-H2030 (pulmonary) ( 442 ) , NCI-H2052 (pulmonary) ( 404 ) , NCI-H2066 (pulmonary) ( 431 ) , NCI-H2073 (pulmonary) ( 110 , 112 , 406 ) , NCI-H209 (pulmonary) ( 112 , 177 ) , NCI-H2106 (pulmonary) ( 109 ) , NCI-H2170 (squamous) ( 503 ) , NCI-H2172 (pulmonary) ( 468 ) , NCI-H2228 (pulmonary) ( 111 , 116 , 265 , 266 , 267 , 487 ) , NCI-H226 (pulmonary) ( 555 ) , NCI-H2286 (pulmonary) ( 441 ) , NCI-H23 (pulmonary) ( 57 , 107 , 216 ) , NCI-H2342 (pulmonary) ( 110 , 405 ) , NCI-H2347 (pulmonary) ( 501 ) , NCI-H2405 (pulmonary) ( 113 ) , NCI-H292 (pulmonary) ( 57 , 143 , 191 ) , NCI-H3122 (pulmonary) ( 111 , 147 , 148 , 155 ) , NCI-H3255 (pulmonary) ( 200 , 231 , 295 , 324 , 325 , 327 , 328 , 379 ) , NCI-H358 (pulmonary) ( 108 , 217 , 505 ) , NCI-H441 (pulmonary) ( 107 , 215 , 314 , 556 , 557 ) , NCI-H446 (pulmonary) ( 580 ) , NCI-H460 (pulmonary) ( 34 , 57 , 97 , 108 , 520 , 550 , 551 , 552 , 554 ) , NCI-H520 (squamous) ( 469 , 470 ) , NCI-H522 (pulmonary) ( 520 ) , NCI-H661 (pulmonary) ( 111 , 474 ) , NCI-H69 (pulmonary) ( 177 ) , NCI-H82 (pulmonary) ( 177 ) , NCI-H838 (pulmonary) ( 112 , 479 ) , NCI-H929 (B lymphocyte) ( 87 ) , NMuMG (epithelial) ( 221 ) , NOZ ('epithelial, gallbladder') ( 253 ) , NT2 (testicular) ( 196 ) , NUGC-2 (gastric) ( 289 ) , NUGC-3 (gastric) ( 285 ) , NUGC-4 (gastric) ( 21 , 30 , 290 ) , Ocy454 ( 61 ) , osteoblast-calvarium ( 424 ) , ovary ( 31 , 41 , 106 , 186 , 308 ) , OVCAR3 (ovarian) ( 41 ) , OVCAR420 (ovarian) ( 184 ) , OVCAR8 (ovarian) ( 41 , 182 , 187 ) , OVKATE (ovarian) ( 178 ) , OVMANA (ovarian) ( 170 ) , OVMIU (ovarian) ( 180 ) , PANC-1 (pancreatic) ( 25 , 26 , 218 , 332 , 542 , 543 ) , PC3 (prostate cell) [CD82 (human)] ( 434 ) , PC3 (prostate cell) ( 28 , 90 , 311 , 313 , 434 , 535 , 604 ) , PC9 (pulmonary) ( 399 ) , PC9-IR (pulmonary) ( 346 ) , placenta ( 602 ) , platelet-blood ( 583 ) , PLC/PRF/5 (hepatic) ( 80 , 103 ) , PLC5 ( 198 ) , QGY-7703 (hepatic) ( 103 ) , R1 ('stem, embryonic') ( 509 ) , Rat1 (fibroblast) ( 306 ) , RAW 264 (macrophage) ( 591 ) , REF52 (fibroblast) ( 313 ) , RERF-GC-1B (gastric) ( 281 ) , RKO (intestinal) ( 18 , 452 ) , RMUG-S (ovarian) ( 179 ) , RWPE1 (prostate cell) ( 28 ) , SACC-83 (salivary gland) ( 257 , 258 ) , Saos-2 (bone cell) ( 61 ) , SCC12 (keratinocyte) ( 568 ) , SCH (gastric) ( 293 ) , SF9 ( 348 ) , SGC7901 (gastric) ( 54 , 96 ) , SHEP (neuron) ( 193 , 612 ) , SK-GT-4 ( 19 ) , SK-HEP-1 (endothelial) ( 198 ) , SK-LU-1 (pulmonary) ( 520 ) , SK-N-BE(2) (neural crest) ( 193 ) , skin ( 246 , 446 ) , SKNAS (neural crest) ( 193 ) , SKOV-3 (ovarian) ( 10 , 41 , 184 , 313 , 581 ) , SNU-1079 (hepatic) ( 247 ) , SNU-398 (hepatic) ( 58 ) , SNU-449 (hepatic) ( 40 , 58 ) , SNU-5 (gastric) ( 364 ) , SNU-668 (gastric) ( 21 , 30 ) , SNU-761 ( 58 ) , SNU-C2B (intestinal) ( 408 , 409 ) , squamous ( 16 ) , stem ( 83 , 305 ) , stomach ( 21 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 260 , 261 ) , stromal ( 62 ) , Su.86.86 (pancreatic) ( 531 ) , SUM159 (breast cell) ( 50 ) , SW-1573 (pulmonary) ( 296 ) , SW480 (intestinal) ( 18 ) , SW620 (intestinal) ( 18 , 312 , 384 , 432 , 433 , 471 , 586 ) , SW780 (bladder cell) ( 344 ) , SYF (fibroblast) ( 171 , 420 , 514 , 595 ) , T lymphocyte ( 78 ) , T24 (bladder cell) ( 27 ) , T47D (breast cell) ( 89 , 192 , 570 ) , T84 (intestinal) ( 315 , 504 ) , T98G (glial) ( 159 , 456 ) , THP1 (myeloid) ( 553 ) , thyroid ( 11 ) , TYK-nu (ovarian) ( 181 ) , U-118MG (glial) ( 152 , 496 ) , U-251 MG (glial) ( 141 , 561 ) , U-937 (myeloid) ( 573 ) , U2OS (bone cell) ( 29 , 102 , 117 ) , U87MG (glial) [EGFR (human), transfection] ( 188 ) , UACC-812 (breast cell) ( 341 , 342 ) , UMSCC1 (squamous) ( 123 ) , VACO432 (ovarian) ( 451 ) , VCap (prostate cell) ( 24 )

Upstream Regulation
Regulatory protein:	ADAM12 (human) ( 50 ) , Akt1 (human) ( 118 ) , Akt1 (mouse) ( 48 ) , ALK1 (human) ( 120 ) , BCAR3 (human) ( 46 ) , CAP1 (human) ( 114 ) , CCL22 (human) ( 23 ) , CD81 (human) ( 62 ) , CDCP1 (human) ( 135 ) , CDK18 (human) ( 74 ) , CEACAM1 (human) ( 303 ) , CEACAM1 iso8 (human) ( 303 ) , COL1A1 (human) ( 7 ) , Cortactin (mouse) ( 176 ) , EMP1 (human) ( 27 ) , ENG (human) ( 120 ) , ER-alpha (human) ( 51 ) , ERK5 (human) ( 49 ) , EXOC4 (human) ( 30 ) , EXOC5 (human) ( 30 ) , FAK (human) ( 280 , 565 ) , FN1 (human) ( 199 ) , FNDC5 (human) ( 35 ) , Fyn (human) ( 171 ) , girdin (human) ( 86 ) , GRP78 (human) ( 103 ) , HCFC1R1 (human) ( 6 ) , HER2 (human) ( 93 , 221 ) , Hic-5 (human) ( 4 ) , HRas (mouse) ( 141 ) , IGF1R (human) ( 225 ) , IHPK2 (human) ( 101 ) , ILK (human) ( 38 ) , ITGA3 (human) ( 72 ) , ITGA5 (human) ( 62 ) , ITGA6 (human) ( 28 , 92 ) , ITGA9 (human) ( 72 ) , ITGB1 (human) ( 24 , 62 , 79 , 199 ) , ITGB4 (human) ( 28 ) , ITGB5 (human) ( 62 ) , JAG1 (mouse) ( 48 ) , KARS (human) ( 121 ) , KIF26A (human) ( 54 ) , Kv11.1 (human) ( 73 ) , LCN2 (human) ( 271 ) , leupaxin (human) ( 4 ) , LKB1 (human) ( 115 ) , LOX (mouse) ( 254 ) , MCPIP1 (human) ( 33 ) , Merlin (human) ( 373 ) , Met (human) ( 420 ) , MIEN1 (human) ( 77 ) , MT1 (human) ( 56 ) , MYCBPAP (human) ( 63 ) , MYH9 (human) ( 75 ) , N-Myc (human) ( 193 ) , p53 (human) ( 9 ) , PAK1 (human) ( 89 ) , PAK4 (human) ( 184 ) , PDCD10 (human) ( 45 ) , PIN1 (human) ( 141 ) , PKCA (human) ( 195 ) , PKCD (human) ( 195 ) , PKM iso2 (human) ( 67 ) , Plectin-1 (human) ( 28 ) , PPAR-gamma (human) ( 27 ) , PTEN (human) ( 28 ) , PTP4A1 (human) ( 334 ) , PTPN13 (human) ( 189 ) , PTPRA (human) ( 95 ) , PXN (human) ( 4 , 122 ) , Pyk2 (human) ( 37 ) , RAB37 (human) ( 59 ) , RAB40B (human) ( 44 ) , RAB5A (human) ( 6 ) , RAC1 (human) ( 102 ) , RACK1 (human) ( 225 ) , RAP1A (human) ( 255 ) , RAP1B (human) ( 255 ) , reelin (human) ( 87 ) , RIOK3 (human) ( 25 ) , RUFY3 (human) ( 6 ) , SAA1 (human) ( 100 ) , SEC6L1 (human) ( 30 ) , SHPS1 (human) ( 188 ) , Siva (human) ( 144 ) , SLK (human) ( 221 ) , Src (human) ( 58 , 336 , 415 , 420 , 514 , 595 ) , STMN1 (human) ( 144 ) , STRAD (human) ( 115 ) , Survivin (human) ( 199 ) , syntenin (human) ( 195 ) , TM4SF5 (human) ( 58 ) , TNC (human) ( 24 ) , TRIM72 (human) ( 42 ) , TXNDC12 (human) ( 96 ) , ULK1 (human) ( 8 ) , Vimentin (human) ( 97 ) , XAB2 (human) ( 20 ) , XIAP (human) ( 199 ) , YAP1 (mouse) ( 48 )
Putative in vivo kinases:	FAK (human) ( 5 , 15 , 21 , 24 , 52 , 61 , 118 , 172 , 313 , 517 , 579 , 597 ) , FGR (human) ( 515 , 583 ) , MARK2 (human) ( 29 ) , Met (human) ( 420 ) , Src (human) ( 33 )
Kinases, in vitro:	FAK (human) ( 52 , 280 , 348 ) , Met (human) ( 420 ) , Src (human) ( 280 )
Putative upstream phosphatases:	DUSP3 (human) ( 71 ) , PTEN (human) ( 597 ) , PTP-PEST (human) ( 141 ) , PTP1B (mouse) ( 440 ) , SHP-2 (human) ( 81 )
Phosphatases, in vitro:	DUSP3 (human) ( 71 ) , PTP-PEST (human) ( 141 )
Treatments:	17-beta-estradiol ( 10 , 51 ) , 2-deoxyribose ( 578 ) , A-443654 ( 312 ) , AG1478 ( 188 , 504 ) , aggregation ( 561 ) , allopurinol ( 419 ) , alpha2-macroglobulin ( 103 ) , antibody ( 23 , 62 , 78 , 578 ) , antimycin_A ( 419 ) , apocynin ( 419 ) , BAPTA-AM ( 504 ) , BI853520 ( 41 ) , blood pressure ( 606 ) , bombesin ( 565 ) , bortezomib ( 335 ) , cabozantinib ( 90 ) , carbachol ( 65 , 315 , 504 ) , carboplatin ( 9 ) , CCL4 ( 37 ) , cell_adhesion ( 43 , 66 , 122 , 176 , 332 , 570 ) , cell_detachment ( 332 , 394 , 520 ) , chrysin ( 55 ) , ciclosporin ( 159 ) , cilengitide ( 61 ) , CNO ( 65 ) , collagen ( 26 , 48 , 434 ) , collagen_I ( 26 , 79 , 195 , 586 ) , collagen_IV ( 437 , 476 , 597 , 613 ) , conditioned medium ( 23 ) , CXCL12 ( 566 ) , cyclic_stretch ( 305 , 314 , 336 , 419 , 508 ) , cycloheximide ( 588 ) , cytochalasin_D ( 332 , 419 , 437 , 504 , 568 ) , dasatinib ( 123 ) , DDC ( 419 ) , defactinib ( 4 , 9 , 16 , 21 , 22 , 61 , 90 ) , deoxycholic_acid ( 347 ) , DIM ( 91 ) , DMSO ( 312 ) , DPI ( 419 ) , dronabinol ( 296 ) , ebastine ( 12 ) , ebselen ( 419 ) , eCF506 ( 38 ) , EGF ( 296 , 315 ) , EphB1 ( 587 ) , ephrin_A1 ( 311 ) , ephrin_B2 ( 201 ) , estetrol ( 13 ) , Ethinylestradiol ( 13 ) , FGF2 ( 83 ) , fibronectin ( 74 , 102 , 117 , 118 , 171 , 195 , 254 , 334 , 434 , 486 , 517 , 568 , 574 , 580 , 595 , 604 , 611 , 612 ) , fluid_shear_stress ( 61 , 596 ) , force ( 85 ) , G-1 ( 10 ) , galardin ( 26 ) , gemcitabine ( 22 ) , genistein ( 504 ) , glabridin ( 140 ) , glucose ( 19 ) , Go_6976 ( 195 , 419 ) , GPI-562 ( 583 ) , GRP ( 565 ) , H2O2 ( 419 , 446 ) , HAMLET ( 175 ) , HGF ( 69 ) , hypoxia ( 50 , 602 ) , ICAM-1 ( 78 ) , IGF-1 ( 225 , 509 , 612 ) , IL-1a ( 591 ) , insulin ( 592 ) , ionizing_radiation ( 7 ) , Irisin ( 62 ) , JWG-045 ( 49 ) , KX2-391 ( 34 ) , laminin peptide ( 47 ) , laminin-1 ( 121 , 434 , 604 ) , laulimalide ( 436 ) , LDL ( 583 ) , liothyronine ( 104 ) , low_potassium ( 120 ) , LPA ( 590 ) , LY294002 ( 312 , 580 , 599 ) , mannitol ( 612 ) , medium change ( 144 ) , metastatic potential ( 472 ) , MFAP5 ( 202 ) , miRNA ( 54 ) , N-nitro-L-arginine ( 419 ) , NAC ( 419 ) , Naphthalene diimide ( 32 ) , nocodazole ( 54 , 144 ) , norcycloartocarpin ( 57 ) , NSC23766 ( 336 ) , NVP-TAE226 ( 15 ) , nystatin ( 120 ) , okadaic_acid ( 612 ) , PAO ( 597 ) , PD98059 ( 601 ) , PDGF ( 118 , 610 ) , pembrolizumab ( 22 ) , PF 573228 ( 5 , 34 , 52 , 59 ) , PF-573228 ( 43 , 69 , 115 , 177 , 313 ) , PF271 ( 17 ) , PF562271 ( 18 , 61 , 67 , 90 , 91 ) , phorbol_ester ( 306 , 419 ) , pioglitazone ( 573 ) , PND-1186 ( 17 , 31 , 38 , 56 , 65 ) , poly-L-lysine ( 304 ) , PP1 ( 69 , 583 ) , PP2 ( 280 , 311 , 314 , 336 , 347 , 504 , 510 , 569 , 579 , 599 , 600 ) , PP3 ( 280 , 311 , 579 ) , pressure ( 312 , 553 ) , PRL ( 89 ) , PTIO ( 15 ) , PTP LYP inhibitor ( 52 ) , RGD ( 572 , 606 ) , Ritanserin ( 34 ) , Ro31-8220 ( 419 ) , rotenone ( 419 ) , rottlerin ( 195 ) , SB202190 ( 122 ) , SB203580 ( 586 ) , SB431542 ( 120 ) , serum ( 596 ) , serum_starvation ( 203 ) , siRNA ( 23 , 34 , 255 , 271 , 334 ) , SKI-606 ( 38 ) , sphingosine_1-phosphate ( 569 ) , staurosporine ( 203 , 588 ) , stiff ECM substrate ( 8 , 26 ) , taxol ( 41 ) , TGF-beta ( 20 , 37 , 120 , 304 , 579 ) , thapsigargin ( 504 ) , thrombin ( 569 , 583 ) , thrombospondin ( 524 ) , TIMP2 ( 417 ) , TNF ( 418 ) , U0126 ( 67 , 141 ) , ultrasound ( 424 ) , vanadate ( 81 , 89 , 417 , 575 , 590 , 597 ) , VEGF ( 47 , 255 , 412 , 436 , 529 , 578 , 591 , 594 , 599 ) , vitronectin ( 604 ) , VS-6766 ( 21 ) , WAY_123398 ( 73 , 486 ) , wortmannin ( 515 ) , Y15 ( 80 , 193 ) , ZINC40099027 ( 52 )

Downstream Regulation
Effects of modification on FAK:	activity, induced ( 34 , 39 ) , enzymatic activity, induced ( 48 , 52 , 67 , 90 , 118 , 172 , 271 , 515 , 587 , 603 , 610 ) , intracellular localization ( 11 , 45 , 508 , 593 , 603 ) , molecular association, regulation ( 42 , 53 , 88 , 97 , 561 , 603 , 610 ) , phosphorylation ( 39 , 48 , 61 , 65 , 67 , 304 , 305 , 607 ) , protein degradation ( 577 )
Effects of modification on biological processes:	apoptosis, altered ( 467 ) , apoptosis, inhibited ( 28 , 193 , 577 , 609 ) , carcinogenesis, induced ( 7 , 9 , 10 , 12 , 17 , 18 , 23 , 27 , 28 , 30 , 33 , 34 , 41 , 45 , 48 , 49 , 50 , 54 , 55 , 57 , 58 , 65 , 67 , 90 , 198 ) , carcinogenesis, inhibited ( 32 , 44 , 141 ) , cell adhesion, altered ( 71 , 193 , 225 , 271 , 373 , 524 , 578 , 588 , 597 , 610 ) , cell adhesion, induced ( 32 , 44 , 49 , 54 , 97 , 141 , 144 ) , cell adhesion, inhibited ( 118 ) , cell differentiation, altered ( 305 ) , cell differentiation, induced ( 54 , 59 ) , cell differentiation, inhibited ( 11 , 45 ) , cell growth, altered ( 172 , 225 , 561 ) , cell growth, induced ( 23 , 28 , 30 , 41 , 55 , 57 , 62 , 65 , 79 , 90 ) , cell motility, altered ( 172 , 199 , 225 , 271 , 373 , 603 ) , cell motility, induced ( 10 , 13 , 18 , 27 , 28 , 29 , 30 , 33 , 34 , 41 , 42 , 50 , 54 , 57 , 58 , 67 , 91 , 118 , 144 ) , cell motility, inhibited ( 32 , 141 ) , cytoskeletal reorganization ( 45 , 144 , 332 , 508 , 587 , 603 ) , DNA repair, induced ( 7 ) , endocytosis, altered ( 607 ) , signaling pathway regulation ( 34 , 41 , 42 , 45 , 54 , 55 , 61 , 67 ) , transcription, altered ( 34 , 304 , 305 , 609 ) , transcription, induced ( 12 , 35 , 37 , 48 , 65 )
Induce interaction with:	FAK (human) ( 603 ) , PIK3R1 (human) ( 610 ) , RASA1 (human) ( 88 , 561 ) , SRC-1 (human) ( 53 ) , Src (human) ( 42 ) , Vimentin (human) ( 97 )
Inhibit interaction with:	PIK3R2 (human) ( 373 ) , Src (human) ( 373 )

Disease / Diagnostics Relevance
Relevant diseases:	breast cancer ( 8 ) , colorectal cancer ( 576 ) , hepatocellular carcinoma ( 198 ) , lung cancer ( 141 ) , ovarian cancer ( 31 , 41 ) , ovarian epithelial carcinoma ( 106 ) , pancreatic ductal adenocarcinoma ( 22 ) , cancer, squamous cell carcinoma ( 571 ) , papillary thyroid carcinoma ( 11 ) , CCA ( 48 )

References
1	Liang P, et al. (2024) Paxillin phase separation promotes focal adhesion assembly and integrin signaling. J Cell Biol 223 38466167 Curated Info
2	Huang M, et al. (2024) ALK upregulates POSTN and WNT signaling to drive neuroblastoma. Cell Rep 43, 113927 38451815 Curated Info
3	Sankar AP, et al. (2024) Antibody-drug conjugate αEGFR-E-P125A reduces triple-negative breast cancer vasculogenic mimicry, motility, and metastasis through inhibition of EGFR, integrin, and FAK/STAT3 signaling. Cancer Res Commun 38315147 Curated Info
4	Fang M, et al. (2024) Paxillin family proteins Hic-5 and LPXN promote lipid storage by regulating the ubiquitination degradation of CIDEC. J Biol Chem 300, 105610 38159847 Curated Info
5	Nazemi M, et al. (2024) The extracellular matrix supports breast cancer cell growth under amino acid starvation by promoting tyrosine catabolism. PLoS Biol 22, e3002406 38227562 Curated Info
6	Khumukcham SS, et al. (2023) HPIP and RUFY3 are noncanonical guanine nucleotide exchange factors of Rab5 to regulate endocytosis-coupled focal adhesion turnover. J Biol Chem 299, 105311 37797694 Curated Info
7	Yang X, et al. (2023) Collagen 1-mediated CXCL1 secretion in tumor cells activates fibroblasts to promote radioresistance of esophageal cancer. Cell Rep 42, 113270 37851572 Curated Info
8	Liang P, et al. (2023) An ULK1/2-PXN mechanotransduction pathway suppresses breast cancer cell migration. EMBO Rep, e56850 37846507 Curated Info
9	Pifer PM, et al. (2023) FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner. Clin Cancer Res 37819945 Curated Info
10	Boscaro C, et al. (2023) MiR-206 inhibits estrogen signaling and ovarian cancer cell migration without affecting GPER. Life Sci, 122135 37778413 Curated Info
11	Ignjatović Jocić V, et al. (2023) Expression of pY397-FAK and Its miR Regulators Drive Dedifferentiation in the Thyroid Neoplasia Spectrum. Cells 12 37443754 Curated Info
12	Seo J, et al. (2023) Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase. Cell Mol Life Sci 80, 132 37185776 Curated Info
13	Dama A, et al. (2023) Regulation of human endothelial cell migration by oral contraceptive estrogen receptor ligands. Eur J Pharmacol 945, 175591 36804546 Curated Info
14	Zhang Y, et al. (2023) FAK-mediated phosphorylation at Y464 regulates p85β nuclear translocation to promote tumorigenesis of ccRCC by repressing RB1 expression. Cell Rep 42, 112188 36857183 Curated Info
15	Zhang J, et al. (2023) Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer. Eur J Med Chem 250, 115192 36801517 Curated Info
16	Zhao H, et al. (2023) Stromal nicotinamide N-methyltransferase orchestrates the crosstalk between fibroblasts and tumour cells in oral squamous cell carcinoma: evidence from patient-derived assembled organoids. Oncogene 36823377 Curated Info
17	Delgado-Bellido D, et al. (2023) VE-Cadherin modulates β-catenin/TCF-4 to enhance Vasculogenic Mimicry. Cell Death Dis 14, 135 36797281 Curated Info
18	Xu C, Zhang W, Liu C (2023) FAK downregulation suppresses stem-like properties and migration of human colorectal cancer cells. PLoS One 18, e0284871 37083591 Curated Info
19	Zhang J, Gelman IH, Qu J, Hochwald SN (2022) Phosphohistidine signaling promotes FAK-RB1 interaction and growth factor-independent proliferation of esophageal squamous cell carcinoma. Oncogene 42 36513743 Curated Info
20	Yakymovych I, et al. (2022) The type II TGF-β receptor phosphorylates Tyr in the type I receptor to activate downstream Src signaling. Sci Signal 15, eabp9521 36378749 Curated Info
21	Peng K, et al. (2022) Development of combination strategies for Focal Adhesion Kinase inhibition in Diffuse Gastric Cancer. Clin Cancer Res 29 36278961 Curated Info
22	Wang-Gillam A, et al. (2022) Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: A phase I, dose escalation, and expansion study. Clin Cancer Res 28 36228156 Curated Info
23	Chen J, et al. (2022) Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC). Cell Mol Immunol 19, 1054-1066 35962191 Curated Info
24	Thomas R, et al. (2022) Androgen receptor variant-7 regulation by tenascin-c induced src activation. Cell Commun Signal 20, 119 35948987 Curated Info
25	Xu M, et al. (2022) RIOK3 promotes pancreatic ductal adenocarcinoma cell invasion and metastasis by stabilizing FAK. Heliyon 8, e10116 35982848 Curated Info
26	Betriu N, Andreeva A, Alonso A, Semino CE (2022) Increased Stiffness Downregulates Focal Adhesion Kinase Expression in Pancreatic Cancer Cells Cultured in 3D Self-Assembling Peptide Scaffolds. Biomedicines 10 36009384 Curated Info
27	Liu S, et al. (2022) Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling. Free Radic Biol Med 189, 42-57 35850179 Curated Info
28	Wenta T, et al. (2022) Disassembly of α6β4-mediated hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin to focal adhesions. Oncogene 41 35773413 Curated Info
29	Pasapera AM, et al. (2022) MARK2 regulates directed cell migration through modulation of myosin II contractility and focal adhesion organization. Curr Biol 32, 2704-2718.e6 35594862 Curated Info
30	Li H, et al. (2022) EXOC4 Promotes Diffuse-Type Gastric Cancer Metastasis via Activating FAK Signal. Mol Cancer Res 20, OF1-OF14 35471457 Curated Info
31	Ozmadenci D, et al. (2022) Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis. Proc Natl Acad Sci U S A 119, e2117065119 35467979 Curated Info
32	Gurung SK, et al. (2022) DNA damage, cell cycle perturbation and cell death by naphthalene diimide derivative in gastric cancer cells. Chem Biol Interact 358, 109881 35307378 Curated Info
33	Gorka J, et al. (2022) MCPIP1 regulates focal adhesion kinase and Rho GTPase-dependent migration in clear cell renal cell carcinoma. Eur J Pharmacol 922, 174804 35257717 Curated Info
34	Fu L, et al. (2022) DGKA interacts with SRC/FAK to promote the metastasis of non-small cell lung cancer. Cancer Lett 532, 215585 35131384 Curated Info
35	He X, et al. (2022) FNDC5/irisin facilitates muscle-adipose-bone connectivity through ubiquitination-dependent activation of runt-related transcriptional factors RUNX1/2. J Biol Chem 298, 101679 35124008 Curated Info
36	Ahmad US, Parkinson EK, Wan H (2022) Desmoglein-3 induces YAP phosphorylation and inactivation during collective migration of oral carcinoma cells. Mol Oncol 16 35000271 Curated Info
37	Huang T, et al. (2022) Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis the FAK/Ras/c-myc/ENO1 pathway. World J Gastroenterol 28, 123-139 35125823 Curated Info
38	Beetham H, et al. (2021) Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors. Cancer Res 82 34921014 Curated Info
39	Velatooru LR, et al. (2021) Disturbed flow-induced FAK K152 SUMOylation initiates the formation of pro-inflammation positive feedback loop by inducing reactive oxygen species production in endothelial cells. Free Radic Biol Med 177, 404-418 34619327 Curated Info
40	Kim E, et al. (2021) TM4SF5-dependent crosstalk between hepatocytes and macrophages to reprogram the inflammatory environment. Cell Rep 37, 110018 34788612 Curated Info
41	Li H, Gao Y, Ren C (2021) Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer. Discov Oncol 12, 29 35201437 Curated Info
42	Dong J, et al. (2021) MG53 inhibits angiogenesis through regulating focal adhesion kinase signalling. J Cell Mol Med 25, 7462-7471 34240802 Curated Info
43	Chan GK, McGrath JA, Parsons M (2021) Spatial activation of ezrin by epidermal growth factor receptor and focal adhesion kinase co-ordinates epithelial cell migration. Open Biol 11, 210166 34375550 Curated Info
44	Linklater ES, et al. (2021) Rab40-Cullin5 complex regulates EPLIN and actin cytoskeleton dynamics during cell migration. J Cell Biol 220 33999101 Curated Info
45	Wang S, et al. (2021) CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling. Nat Cell Biol 23, 758-770 34226698 Curated Info
46	Steenkiste EM, et al. (2021) A Cas-BCAR3 co-regulatory circuit controls lamellipodia dynamics. Elife 10 34169835 Curated Info
47	Richards M, et al. (2021) Intra-vessel heterogeneity establishes enhanced sites of macromolecular leakage downstream of laminin α5. Cell Rep 35, 109268 34161758 Curated Info
48	Song X, et al. (2021) Focal Adhesion Kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. J Hepatol 75 34052254 Curated Info
49	Xu Q, et al. (2021) The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion. Oncogene 40 33981002 Curated Info
50	Wang R, et al. (2021) Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis. Proc Natl Acad Sci U S A 118 33952697 Curated Info
51	Saimi M, et al. (2021) Cytonuclear Estrogen Receptor Alpha Regulates Proliferation and Migration of Endometrial Carcinoma Cells. Tokai J Exp Clin Med 46, 7-16 33835469 Curated Info
52	Rashmi null, et al. (2021) ZINC40099027 activates human focal adhesion kinase by accelerating the enzymatic activity of the FAK kinase domain. Pharmacol Res Perspect 9, e00737 33715263 Curated Info
53	Higuchi M, et al. (2021) Paradoxical activation of c-Src as a drug-resistant mechanism. Cell Rep 34, 108876 33761359 Curated Info
54	Ma RR, et al. (2021) MiR-19a/miR-96-mediated low expression of KIF26A suppresses metastasis by regulating FAK pathway in gastric cancer. Oncogene 40 33674746 Curated Info
55	Chen J, et al. (2021) Chrysin serves as a novel inhibitor of DGK/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). Acta Pharm Sin B 11, 143-155 33532186 Curated Info
56	Thakur V, et al. (2021) MT1-MMP-dependent ECM processing regulates laminB1 stability and mediates replication fork restart. PLoS One 16, e0253062 34237080 Curated Info
57	Nonpanya N, et al. (2021) Norcycloartocarpin targets Akt and suppresses Akt-dependent survival and epithelial-mesenchymal transition in lung cancer cells. PLoS One 16, e0254929 34383763 Curated Info
58	Song HE, et al. (2021) N-terminus-independent activation of c-Src via binding to a tetraspan(in) TM4SF5 in hepatocellular carcinoma is abolished by the TM4SF5 C-terminal peptide application. Theranostics 11, 8092-8111 34335982 Curated Info
59	Huang H, et al. (2021) RAB37 Promotes Adipogenic Differentiation of hADSCs via the TIMP1/CD63/Integrin Signaling Pathway. Stem Cells Int 2021, 8297063 34858503 Curated Info
60	Acebr¿¿n I, et al. (2020) Structural basis of Focal Adhesion Kinase activation on lipid membranes. EMBO J 32779739 Curated Info
61	Sato T, et al. (2020) A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction. Nat Commun 11, 3282 32612176 Curated Info
62	Oguri Y, et al. (2020) CD81 Controls Beige Fat Progenitor Cell Growth and Energy Balance via FAK Signaling. Cell 32615086 Curated Info
63	Tsutaho A, et al. (2020) High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer. Cell Commun Signal 32580737 Curated Info
64	Gunesch JT, et al. (2020) CD56 regulates human NK cell cytotoxicity through Pyk2. Elife 32510326 Curated Info
65	Goto Y, et al. (2020) Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK-YAP signaling axis. Oncogene 39 32205868 Curated Info
66	Park JS, et al. (2020) Mechanical regulation of glycolysis via cytoskeleton architecture. Nature 578 32051585 Curated Info
67	Wang C, et al. (2020) Secreted Pyruvate Kinase M2 Promotes Lung Cancer Metastasis through Activating the Integrin Beta1/FAK Signaling Pathway. Cell Rep 30 32049010 Curated Info
68	Ruggiero C, et al. (2018) The KDEL receptor signalling cascade targets focal adhesion kinase on focal adhesions and invadopodia. Oncotarget 9, 10228-10246 29535802 Curated Info
69	Gayrard C, et al. (2018) Src- and confinement-dependent FAK activation causes E-cadherin relaxation and β-catenin activity. J Cell Biol 217 29311227 Curated Info
70	Genna A, et al. (2018) Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells. J Cell Biol 217, 375-395 29133485 Curated Info
71	Chen YR, et al. (2017) Deficiency in VHR/DUSP3, a suppressor of focal adhesion kinase, reveals its role in regulating cell adhesion and migration. Oncogene 36, 6509-6517 28759036 Curated Info
72	Longmate WM, et al. (2017) Suppression of integrin α3β1 by α9β1 in the epidermis controls the paracrine resolution of wound angiogenesis. J Cell Biol 216, 1473-1488 28416479 Curated Info
73	Becchetti A, et al. (2017) The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression. Sci Signal 10 28377405 Curated Info
74	Matsuda S, et al. (2017) PCTK3/CDK18 regulates cell migration and adhesion by negatively modulating FAK activity. Sci Rep 7, 45545 28361970 Curated Info
75	Rai V, Thomas DG, Beach JR, Egelhoff TT (2017) Myosin IIA Heavy Chain Phosphorylation Mediates Adhesion Maturation and Protrusion in Three Dimensions. J Biol Chem 292, 3099-3111 28053086 Curated Info
76	Cheng Z, et al. (2017) Focal Adhesion Kinase-mediated Phosphorylation of Beclin1 Protein Suppresses Cardiomyocyte Autophagy and Initiates Hypertrophic Growth. J Biol Chem 292, 2065-2079 27994061 Curated Info
77	Wang Y, et al. (2017) Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth. Oncogene 36, 756-765 27399332 Curated Info
78	Eppler FJ, Quast T, Kolanus W (2017) Dynamin2 controls Rap1 activation and integrin clustering in human T lymphocyte adhesion. PLoS One 12, e0172443 28273099 Curated Info
79	Begum A, et al. (2017) The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLoS One 12, e0180181 28692661 Curated Info
80	Wong KF, et al. (2016) Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma. Oncotarget 7, 77683-77695 27765911 Curated Info
81	Choi I, et al. (2016) LRRK2 Inhibits FAK Activity by Promoting FERM-mediated Autoinhibition of FAK and Recruiting the Tyrosine Phosphatase, SHP-2. Exp Neurobiol 25, 269-276 27790061 Curated Info
82	Kimani SG, et al. (2016) Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase. Cell Commun Signal 14, 19 27595981 Curated Info
83	Burgett ME, et al. (2016) Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells. Oncotarget 7, 43852-43867 27270311 Curated Info
84	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
85	Scott DW, Tolbert CE, Burridge K (2016) Tension on JAM-A activates RhoA via GEF-H1 and p115 RhoGEF. Mol Biol Cell 27, 1420-30 26985018 Curated Info
86	Leyme A, Marivin A, Garcia-Marcos M (2016) GIV/Girdin (Gα-interacting, Vesicle-associated Protein/Girdin) Creates a Positive Feedback Loop That Potentiates Outside-in Integrin Signaling in Cancer Cells. J Biol Chem 291, 8269-82 26887938 Curated Info
87	Lin L, et al. (2016) Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3. Oncotarget 7, 9844-58 26848618 Curated Info
88	Antoine-Bertrand J, et al. (2016) p120RasGAP Protein Mediates Netrin-1 Protein-induced Cortical Axon Outgrowth and Guidance. J Biol Chem 291, 4589-602 26710849 Curated Info
89	Hammer A, Diakonova M (2016) Prolactin-induced PAK1 tyrosyl phosphorylation promotes FAK dephosphorylation, breast cancer cell motility, invasion and metastasis. BMC Cell Biol 17, 31 27542844 Curated Info
90	Lee YC, et al. (2015) Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res 75, 4949-59 26530902 Curated Info
91	Li WX, et al. (2015) 3'3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling. Oncotarget 6, 23776-92 26068982 Curated Info
92	Nam SH, et al. (2015) Noncanonical roles of membranous lysyl-tRNA synthetase in transducing cell-substrate signaling for invasive dissemination of colon cancer spheroids in 3D collagen I gels. Oncotarget 6, 21655-74 26091349 Curated Info
93	Lakshmanan I, et al. (2015) Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Oncotarget 6, 21085-99 26035354 Curated Info
94	Ibrahim R, Lemoine A, Bertoglio J, Raingeaud J (2015) Human enhancer of filamentation 1-induced colorectal cancer cell migration: Role of serine phosphorylation and interaction with the breast cancer anti-estrogen resistance 3 protein. Int J Biochem Cell Biol 64, 45-57 25817040 Curated Info
95	Fang XQ, et al. (2015) Focal adhesion kinase regulates the phosphorylation protein tyrosine phosphatase-α at Tyr789 in breast cancer cells. Mol Med Rep 11, 4303-8 25625869 Curated Info
96	Wu J, et al. (2015) ERp19 contributes to tumorigenicity in human gastric cancer by promoting cell growth, migration and invasion. Oncotarget 6, 11794-805 25940440 Curated Info
97	Havel LS, Kline ER, Salgueiro AM, Marcus AI (2015) Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene 34, 1979-90 24858039 Curated Info
98	Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130 25884760 Curated Info
99	Ravi A, et al. (2015) Epidermal Growth Factor Activates the Rho GTPase-activating Protein (GAP) Deleted in Liver Cancer 1 via Focal Adhesion Kinase and Protein Phosphatase 2A. J Biol Chem 290, 4149-62 25525271 Curated Info
100	Lung HL, et al. (2015) SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma. Oncogene 34, 878-89 24608426 Curated Info
101	Rao F, et al. (2015) Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1. Proc Natl Acad Sci U S A 112, 1773-8 25617365 Curated Info
102	Pasapera AM, et al. (2015) Rac1-Dependent Phosphorylation and Focal Adhesion Recruitment of Myosin IIA Regulates Migration and Mechanosensing. Curr Biol 25, 175-86 25544611 Curated Info
103	Zhao S, et al. (2015) The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated α2M. BMC Cancer 15, 389 25958313 Curated Info
104	Park JW, Zhao L, Webb P, Cheng SY (2014) Src-dependent phosphorylation at Y406 on the thyroid hormone receptor β confers the tumor suppressor activity. Oncotarget 5, 10002-16 25275301 Curated Info
105	Guilluy C, et al. (2014) Isolated nuclei adapt to force and reveal a mechanotransduction pathway in the nucleus. Nat Cell Biol 16, 376-81 24609268 Curated Info
106	Aust S, et al. (2014) Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium. Mol Cancer 13, 67 24655477 Curated Info
107	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
108	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
109	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
110	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
111	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
112	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
113	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
114	Zhang H, et al. (2013) Mammalian Adenylyl Cyclase-associated Protein 1 (CAP1) Regulates Cofilin Function, the Actin Cytoskeleton, and Cell Adhesion. J Biol Chem 288, 20966-77 23737525 Curated Info
115	Kline ER, et al. (2013) LKB1 represses focal adhesion kinase (FAK) signaling via a FAK-LKB1 complex to regulate FAK site maturation and directional persistence. J Biol Chem 288, 17663-74 23637231 Curated Info
116	Rikova K (2013) CST Curation Set: 18449; Year: 2012; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954 Curated Info
117	Feng Y, et al. (2013) α-actinin1 and 4 tyrosine phosphorylation is critical for stress fiber establishment, maintenance and focal adhesion maturation. Exp Cell Res 319, 1124-35 23454549 Curated Info
118	Higuchi M, et al. (2013) Akt1 promotes focal adhesion disassembly and cell motility through phosphorylation of FAK in growth factor-stimulated cells. J Cell Sci 126, 745-55 23264741 Curated Info
119	Johnson H, et al. (2012) Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts. Mol Cell Proteomics 11, 1724-40 22964225 Curated Info
120	Tian H, et al. (2012) Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells. EMBO J 31, 3885-900 22940691 Curated Info
121	Kim DG, et al. (2012) Interaction of two translational components, lysyl-tRNA synthetase and p40/37LRP, in plasma membrane promotes laminin-dependent cell migration. FASEB J 26, 4142-59 22751010 Curated Info
122	Kwak TK, et al. (2012) Cell adhesion-dependent serine 85 phosphorylation of paxillin modulates focal adhesion formation and haptotactic migration via association with the C-terminal tail domain of talin. J Biol Chem 287, 27499-509 22761432 Curated Info
123	Wheeler SE, et al. (2012) Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clin Cancer Res 18, 2850-60 22490227 Curated Info
124	Rikova K (2012) CST Curation Set: 14270; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 1mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
125	Rikova K (2012) CST Curation Set: 14271; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
126	Possemato A (2012) CST Curation Set: 14060; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
127	Possemato A (2012) CST Curation Set: 14061; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
128	Possemato A (2012) CST Curation Set: 14062; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
129	Possemato A (2012) CST Curation Set: 14063; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
130	Possemato A (2012) CST Curation Set: 14058; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
131	Possemato A (2012) CST Curation Set: 14059; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
132	Zhou J (2012) CST Curation Set: 13888; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876 Curated Info
133	Zhou J (2012) CST Curation Set: 13889; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876 Curated Info
134	Zhou J (2012) CST Curation Set: 13898; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876 Curated Info
135	Benes CH, Poulogiannis G, Cantley LC, Soltoff SP (2012) The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility. Oncogene 31, 653-63 21725358 Curated Info
136	Mulhern D (2012) CST Curation Set: 13331; Year: 2012; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Curated Info
137	Mulhern D (2012) CST Curation Set: 13332; Year: 2012; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Curated Info
138	Mulhern D (2012) CST Curation Set: 13333; Year: 2012; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876 Curated Info
139	Tomar A, Lawson C, Ghassemian M, Schlaepfer DD (2012) Cortactin as a Target for FAK in the Regulation of Focal Adhesion Dynamics. PLoS One 7, e44041 22952866 Curated Info
140	Tsai YM, et al. (2011) Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/rho signaling pathway. Integr Cancer Ther 10, 341-9 21059620 Curated Info
141	Zheng Y, et al. (2011) Ras-Induced and Extracellular Signal-Regulated Kinase 1 and 2 Phosphorylation-Dependent Isomerization of Protein Tyrosine Phosphatase (PTP)-PEST by PIN1 Promotes FAK Dephosphorylation by PTP-PEST. Mol Cell Biol 31, 4258-69 21876001 Curated Info
142	Morello V, et al. (2011) β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene 30, 4087-96 21478906 Curated Info
143	Li C, et al. (2011) Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene 30, 3802-12 21478903 Curated Info
144	Li N, et al. (2011) Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Proc Natl Acad Sci U S A 108, 12851-6 21768358 Curated Info
145	Possemato A (2011) CST Curation Set: 11905; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
146	Possemato A (2011) CST Curation Set: 11906; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
147	Possemato A (2011) CST Curation Set: 11907; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
148	Possemato A (2011) CST Curation Set: 11908; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
149	Possemato A (2011) CST Curation Set: 11909; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
150	Possemato A (2011) CST Curation Set: 11911; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
151	Possemato A (2011) CST Curation Set: 11912; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
152	Possemato A (2011) CST Curation Set: 11915; Year: 2011; Biosample/Treatment: cell line, U118 MG/untreated; Disease: astrocytoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
153	Possemato A (2011) CST Curation Set: 11917; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
154	Possemato A (2011) CST Curation Set: 11918; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
155	Possemato A (2011) CST Curation Set: 11919; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
156	Possemato A (2011) CST Curation Set: 11921; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
157	Possemato A (2011) CST Curation Set: 11922; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
158	Possemato A (2011) CST Curation Set: 11924; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
159	Kwiatkowska A, et al. (2011) Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression. Biochim Biophys Acta 1813, 655-67 21276823 Curated Info
160	Ren H (2011) CST Curation Set: 11773; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
161	Ren H (2011) CST Curation Set: 11778; Year: 2011; Biosample/Treatment: cell line, RP95/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
162	Ren H (2011) CST Curation Set: 11784; Year: 2011; Biosample/Treatment: cell line, RP101/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
163	Ren H (2011) CST Curation Set: 11785; Year: 2011; Biosample/Treatment: cell line, RP102/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
164	Ren H (2011) CST Curation Set: 11787; Year: 2011; Biosample/Treatment: cell line, RP104/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
165	Ren H (2011) CST Curation Set: 11791; Year: 2011; Biosample/Treatment: cell line, FAC 13T/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
166	Deramaudt TB, et al. (2011) FAK phosphorylation at Tyr-925 regulates cross-talk between focal adhesion turnover and cell protrusion. Mol Biol Cell 22, 964-75 21289086 Curated Info
167	Kuo JC, et al. (2011) Analysis of the myosin-II-responsive focal adhesion proteome reveals a role for β-Pix in negative regulation of focal adhesion maturation. Nat Cell Biol 13, 383-93 21423176 Curated Info
168	Li Y (2011) CST Curation Set: 10524; Year: 2011; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
169	Chumbalkar V, et al. (2011) Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of ΔEGFR. J Proteome Res 10, 1343-52 21214269 Curated Info
170	Ren H (2011) CST Curation Set: 11303; Year: 2011; Biosample/Treatment: cell line, OVMANA/serum starved; Disease: ovarian epithelial carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
171	Yeo MG, et al. (2011) Phosphorylation of Ser 21 in Fyn regulates its kinase activity, focal adhesion targeting, and is required for cell migration. J Cell Physiol 226, 236-47 20658524 Curated Info
172	Chen TH, Chan PC, Chen CL, Chen HC (2011) Phosphorylation of focal adhesion kinase on tyrosine 194 by Met leads to its activation through relief of autoinhibition. Oncogene 30, 153-66 20802513 Curated Info
173	Gu TL, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640 21253578 Curated Info
174	Ding VM, et al. (2011) Tyrosine phosphorylation profiling in fgf-2 stimulated human embryonic stem cells. PLoS One 6, e17538 21437283 Curated Info
175	Trulsson M, et al. (2011) HAMLET binding to α-actinin facilitates tumor cell detachment. PLoS One 6, e17179 21408150 Curated Info
176	Wang W, Liu Y, Liao K (2011) Tyrosine phosphorylation of cortactin by the FAK-Src complex at focal adhesions regulates cell motility. BMC Cell Biol 12, 49 22078467 Curated Info
177	Ocak S, et al. (2010) DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene 29, 6331-42 20802517 Curated Info
178	Ren H (2010) CST Curation Set: 10743; Year: 2010; Biosample/Treatment: cell line, OVKATE/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
179	Ren H (2010) CST Curation Set: 10753; Year: 2010; Biosample/Treatment: cell line, RMUG-S/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
180	Ren H (2010) CST Curation Set: 10754; Year: 2010; Biosample/Treatment: cell line, OVMIU/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
181	Ren H (2010) CST Curation Set: 10751; Year: 2010; Biosample/Treatment: cell line, TYK-nu/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
182	Ren H (2010) CST Curation Set: 10756; Year: 2010; Biosample/Treatment: cell line, OVCAR8/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
183	Knowlton ML, et al. (2010) Profiling Y561-Dependent and -Independent Substrates of CSF-1R in Epithelial Cells. PLoS One 5, e13587 21049007 Curated Info